Sponsored by
Proud to say that the Musella Foundation helped to fund this project! It is a new approach to brain tumor treatment targeting the iron metabolism in the cells. The conclusion of this study in lab rats was: "Monotherapy with the iron-mimetic GaM profoundly inhibits trGBM growth and significantly extends disease-specific survival in vivo." This is in a clinical trial in recurrent Glioblastoma now. It is an oral drug apparently without major side effects. We will keep a close eye on this.